CN111617245A - 一种消炎多用女性阴道泡沫剂 - Google Patents
一种消炎多用女性阴道泡沫剂 Download PDFInfo
- Publication number
- CN111617245A CN111617245A CN202010634558.0A CN202010634558A CN111617245A CN 111617245 A CN111617245 A CN 111617245A CN 202010634558 A CN202010634558 A CN 202010634558A CN 111617245 A CN111617245 A CN 111617245A
- Authority
- CN
- China
- Prior art keywords
- parts
- inflammatory
- vagina
- triethanolamine
- multipurpose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 18
- 210000001215 vagina Anatomy 0.000 title abstract description 20
- 239000006260 foam Substances 0.000 title description 2
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000009141 Houttuynia cordata plant extract Substances 0.000 claims abstract description 15
- 229920001661 Chitosan Polymers 0.000 claims abstract description 13
- 238000004140 cleaning Methods 0.000 claims abstract description 12
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 11
- 239000002131 composite material Substances 0.000 claims abstract description 11
- 239000004088 foaming agent Substances 0.000 claims abstract description 11
- 229930014456 matrine Natural products 0.000 claims abstract description 11
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 9
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 9
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims abstract description 7
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims abstract description 7
- 229960003942 amphotericin b Drugs 0.000 claims abstract description 7
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 6
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 6
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 6
- 239000003240 coconut oil Substances 0.000 claims abstract description 6
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 6
- 239000008367 deionised water Substances 0.000 claims abstract description 6
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 6
- 229930195729 fatty acid Natural products 0.000 claims abstract description 6
- 239000000194 fatty acid Substances 0.000 claims abstract description 6
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 6
- 239000010681 turmeric oil Substances 0.000 claims abstract description 6
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 229930013930 alkaloid Natural products 0.000 claims description 10
- 235000013601 eggs Nutrition 0.000 claims description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 229960004022 clotrimazole Drugs 0.000 claims description 8
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 8
- 229960000282 metronidazole Drugs 0.000 claims description 8
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 239000003973 paint Substances 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- -1 alkali metal salt Chemical class 0.000 claims description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 5
- 238000010009 beating Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 5
- 230000003472 neutralizing effect Effects 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 240000000691 Houttuynia cordata Species 0.000 claims description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229940044952 vaginal foam Drugs 0.000 claims 5
- 239000000259 vaginal foam Substances 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 10
- 201000008100 Vaginitis Diseases 0.000 abstract description 7
- 208000006374 Uterine Cervicitis Diseases 0.000 abstract description 6
- 206010046914 Vaginal infection Diseases 0.000 abstract description 6
- 206010008323 cervicitis Diseases 0.000 abstract description 6
- 230000033228 biological regulation Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 4
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 abstract description 4
- 102000002322 Egg Proteins Human genes 0.000 abstract description 3
- 108010000912 Egg Proteins Proteins 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 235000013345 egg yolk Nutrition 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000000922 anti-bactericidal effect Effects 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 239000012459 cleaning agent Substances 0.000 abstract description 2
- 239000000645 desinfectant Substances 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 239000004310 lactic acid Substances 0.000 abstract description 2
- 235000014655 lactic acid Nutrition 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 208000004880 Polyuria Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003467 diminishing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000003453 lung abscess Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 241000223600 Alternaria Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种消炎多用女性阴道泡沫剂，其包括：醋酸氯己定、椰子油脂肪酸二乙醇酰胺、三乙醇胺、复合卵黄抗体、两性霉素B、壳聚糖、鱼腥草提取液、莪术油、苦参碱剂和去离子水。包含复合卵黄抗体为活性成分，通过对阴道内的六种致病菌的杀灭，调节阴道内环境，使其pH恢复并保持在弱酸性状态，促进乳酸菌等优势菌种的繁殖，从菌群调节的角度，有效预防或治疗妇科炎症疾病如阴道炎、宫颈炎等。通过采用各类消炎杀菌药物，配合鱼腥草提取液等中草药洗剂对阴道内部进行清洗消毒并杀菌，配合菌群调节进行杀菌消毒在短时间内消除病症。
Description
技术领域
本发明应用于阴道消炎领域，具体是一种消炎多用女性阴道泡沫剂。
背景技术
妇科炎症是妇科门诊的常见疾病，其中阴道炎、宫颈炎是常见的妇科炎症疾病，其发病多与患者阴道微生态不平衡有关，且治疗效果较差，复发率高。阴道炎、宫颈炎的主要病理改变是阴道内的菌群失调，即正常寄生在阴道内的微生态菌群失调，阴道内乳酸杆菌等有益菌减少而使其他细菌大量繁殖，厌氧菌繁殖同时产生胺类物质，碱化阴道，使阴道分泌物增多并产生异味。因此，预防和治疗阴道炎、宫颈炎的关键是调节患者体内的阴道菌群趋于平衡。
现有技术中对于阴道炎、宫颈炎等常见妇科炎症的治疗多为单独采用抗炎治疗或单独采用菌群调节治疗；单独采用抗炎治疗的妇科用产品中大部分是抗生素，长期使用易产生耐药性，并破坏了女性阴道内正常菌群的平衡，导致炎症的反复发作、难以根治。单独采用菌群调节治疗无法快速对已有炎症进行消炎杀菌，起效慢，容易拖延病情使其恶化。
发明内容
本发明的目的在于克服现有技术的不足，提供一种消炎多用女性阴道泡沫剂。
为实现上述目的，本发明采用如下技术方案：一种消炎多用女性阴道泡沫剂，其包括如下重量份数的各组分：
醋酸氯己定 7.5-22.5份；
椰子油脂肪酸二乙醇酰胺 160-180份；
三乙醇胺 100-250份；
复合卵黄抗体 6.5-25份；
两性霉素B 2.4-8.6份；
壳聚糖 7-15份；
鱼腥草提取液 70-200份；
莪术油 50-200份；
苦参碱剂 30-75份；
去离子水 500-6000份。
进一步的，所述复合卵黄抗体为卵黄抗体粉，其制备方法如下：S1：将所述鸡蛋经清洗、打蛋分离后得到卵黄；S2：均质、巴氏杀菌；S3：进行喷雾干燥，获得卵黄抗体粉。
进一步的，其还包括如下重量份数的各组分：甲硝唑6.5-8份；克霉唑4.5-6.5份。
进一步的，所述三乙醇胺精制方法为将三乙醇胺含量在80%以上的工业品用水蒸气蒸馏除去乙醇胺，加入氢氧化钠使三乙醇胺成碱金属盐而析出，分离后中和，再进行减压蒸馏得纯品。
进一步的，所述鱼腥草提取液制备过程包括如下步骤：S1：将新鲜鱼腥草洗净后粉碎、过筛，加入乙醇，在75～100℃回流提取4-6小时，料液重量体积比为1:22～30；S2：将提取液过滤、经真空浓缩至无醇味；S3：在紫外线消毒灯下消毒1-2h。
进一步的，所述苦参碱剂制备过程包括如下步骤：S1：取苦参总生物碱6g，加水溶解；S2：以5mol/L盐酸调节PH至6；S3：将十二醇硫酸钠0.12g、十八醇0.2g和羊毛醇0.15g置水浴上融化后倒入苦参总生物碱水溶液中；S4：加入甘油5g搅拌均匀。
本发明采用以上技术方案，包含复合卵黄抗体为活性成分，通过对阴道内的六种致病菌的杀灭，调节阴道内环境，使其pH恢复并保持在弱酸性状态(pH值约为3.8～4.5)，促进乳酸菌等优势菌种的繁殖，从菌群调节的角度，有效预防或治疗妇科炎症疾病如阴道炎、宫颈炎等。通过采用各类消炎杀菌药物，配合鱼腥草提取液等中草药洗剂对阴道内部进行清洗消毒并杀菌，配合菌群调节进行杀菌消毒在短时间内消除病症。
具体实施方式
实施例1
一种消炎多用女性阴道泡沫剂，其包括如下重量份数的各组分：
醋酸氯己定 12份；
椰子油脂肪酸二乙醇酰胺 170份；
三乙醇胺 180份；
复合卵黄抗体 15份；
两性霉素B 6份；
壳聚糖 10份；
鱼腥草提取液 120份；
莪术油 150份；
苦参碱剂 50份；
去离子水 3000份。
进一步的，所述复合卵黄抗体为卵黄抗体粉，其制备方法如下：S1：将所述鸡蛋经清洗、打蛋分离后得到卵黄；S2：均质、巴氏杀菌；S3：进行喷雾干燥，获得卵黄抗体粉。
进一步的，其还包括如下重量份数的各组分：甲硝唑7份；克霉唑5份。甲硝唑、克霉唑、醋酸氯己定泡沫剂具有柔和、细腻、无刺激、良好的吸附性和扩张性等优点，能深入黏膜褶皱等一般药物难以达到的部位，与病灶充分接触，全面杀菌，不留死角，而且形成保护膜，预防感染，且患者用药的感觉舒适。
进一步的，所述三乙醇胺精制方法为将三乙醇胺含量在80%以上的工业品用水蒸气蒸馏除去乙醇胺，加入氢氧化钠使三乙醇胺成碱金属盐而析出，分离后中和，再进行减压蒸馏得纯品。
进一步的，所述鱼腥草提取液制备过程包括如下步骤：S1：将新鲜鱼腥草洗净后粉碎、过筛，加入乙醇，在100℃回流提取6小时，料液重量体积比为1:30；S2：将提取液过滤、经真空浓缩至无醇味；S3：在紫外线消毒灯下消毒2h。鱼腥草味辛，性寒凉，归肺经。能清热解毒、消肿疗疮、利尿除湿、清热止痢、健胃消食，用治实热、热毒、湿邪、疾热为患的肺痈、疮疡肿毒、痔疮便血、脾胃积热等。现代药理实验表明，本品具有抗菌、抗病毒、提高机体免疫力、利尿等作用。利用鱼腥草提取液对阴道内壁进行抗菌消炎。
进一步的，所述苦参碱剂制备过程包括如下步骤：S1：取苦参总生物碱6g，加水溶解；S2：以5mol/L盐酸调节PH至6；S3：将十二醇硫酸钠0.12g、十八醇0.2g和羊毛醇0.15g置水浴上融化后倒入苦参总生物碱水溶液中；S4：加入甘油5g搅拌均匀。
壳聚糖具有较强的抗真菌性。抑菌实验发现壳聚糖对薄状菌属、脉孢菌属、座线孢菌属等32种真菌具有抑制作用。一般地，当壳聚糖的浓度达到100μg/mL时，即可表现出抗真菌性，且抗真菌性与壳聚糖颗粒的大小成反比。壳聚糖的聚合度对其抗真菌性有较大的影响，聚合度降低，则壳聚糖所能抑制的真菌种类减少，但抑制的程度加强。
两性霉素B用于隐球菌、球孢子菌、荚膜组织胞浆菌、芽生菌、孢子丝菌、念珠菌、毛霉、曲菌等引起的内脏或全身感染。
实施例2
本发明提供了一种消炎多用女性阴道泡沫剂，其包括如下重量份数的各组分：
醋酸氯己定 7.5份；
椰子油脂肪酸二乙醇酰胺 160份；
三乙醇胺 100份；
复合卵黄抗体 6.5份；
两性霉素B 2.4份；
壳聚糖 7份；
鱼腥草提取液 70份；
莪术油 50份；
苦参碱剂 305份；
去离子水 500份。
进一步的，所述复合卵黄抗体为卵黄抗体粉，其制备方法如下：S1：将所述鸡蛋经清洗、打蛋分离后得到卵黄；S2：均质、巴氏杀菌；S3：进行喷雾干燥，获得卵黄抗体粉。
进一步的，其还包括如下重量份数的各组分：甲硝唑6.5份；克霉唑4.5份。甲硝唑、克霉唑、醋酸氯己定泡沫剂具有柔和、细 腻、无刺激、良好的吸附性和扩张性等优点，能深入黏膜褶皱等一般药物难以达到的部位，与病灶充分接触，全面杀菌，不留死角，而且形成保护膜，预防感染，且患者用药的感觉舒适。
进一步的，所述三乙醇胺精制方法为将三乙醇胺含量在80%以上的工业品用水蒸气蒸馏除去乙醇胺，加入氢氧化钠使三乙醇胺成碱金属盐而析出，分离后中和，再进行减压蒸馏得纯品。
进一步的，所述鱼腥草提取液制备过程包括如下步骤：S1：将新鲜鱼腥草洗净后粉碎、过筛，加入乙醇，在100℃回流提取6小时，料液重量体积比为1:30；S2：将提取液过滤、经真空浓缩至无醇味；S3：在紫外线消毒灯下消毒2h。鱼腥草味辛，性寒凉，归肺经。能清热解毒、消肿疗疮、利尿除湿、清热止痢、健胃消食，用治实热、热毒、湿邪、疾热为患的肺痈、疮疡肿毒、痔疮便血、脾胃积热等。现代药理实验表明，本品具有抗菌、抗病毒、提高机体免疫力、利尿等作用。利用鱼腥草提取液对阴道内壁进行抗菌消炎。
进一步的，所述苦参碱剂制备过程包括如下步骤：S1：取苦参总生物碱6g，加水溶解；S2：以5mol/L盐酸调节PH至6；S3：将十二醇硫酸钠0.12g、十八醇0.2g和羊毛醇0.15g置水浴上融化后倒入苦参总生物碱水溶液中；S4：加入甘油5g搅拌均匀。
实施例3
一种消炎多用女性阴道泡沫剂，其包括如下重量份数的各组分：
醋酸氯己定 22.5份；
椰子油脂肪酸二乙醇酰胺 180份；
三乙醇胺 250份；
复合卵黄抗体 25份；
两性霉素B 8.6份；
壳聚糖 15份；
鱼腥草提取液 200份；
莪术油 200份；
苦参碱剂 75份；
去离子水 6000份。
进一步的，所述复合卵黄抗体为卵黄抗体粉，其制备方法如下：S1：将所述鸡蛋经清洗、打蛋分离后得到卵黄；S2：均质、巴氏杀菌；S3：进行喷雾干燥，获得卵黄抗体粉。
进一步的，其还包括如下重量份数的各组分：甲硝唑8份；克霉唑6.5份。甲硝唑、克霉唑、醋酸氯己定泡沫剂具有柔和、细 腻、无刺激、良好的吸附性和扩张性等优点，能深入黏膜褶皱等一般药物难以达到的部位，与病灶充分接触，全面杀菌，不留死角，而且形成保护膜，预防感染，且患者用药的感觉舒适。
进一步的，所述三乙醇胺精制方法为将三乙醇胺含量在80%以上的工业品用水蒸气蒸馏除去乙醇胺，加入氢氧化钠使三乙醇胺成碱金属盐而析出，分离后中和，再进行减压蒸馏得纯品。
进一步的，所述鱼腥草提取液制备过程包括如下步骤：S1：将新鲜鱼腥草洗净后粉碎、过筛，加入乙醇，在100℃回流提取6小时，料液重量体积比为1:30；S2：将提取液过滤、经真空浓缩至无醇味；S3：在紫外线消毒灯下消毒2h。鱼腥草味辛，性寒凉，归肺经。能清热解毒、消肿疗疮、利尿除湿、清热止痢、健胃消食，用治实热、热毒、湿邪、疾热为患的肺痈、疮疡肿毒、痔疮便血、脾胃积热等。现代药理实验表明，本品具有抗菌、抗病毒、提高机体免疫力、利尿等作用。利用鱼腥草提取液对阴道内壁进行抗菌消炎。
进一步的，所述苦参碱剂制备过程包括如下步骤：S1：取苦参总生物碱6g，加水溶解；S2：以5mol/L盐酸调节PH至6；S3：将十二醇硫酸钠0.12g、十八醇0.2g和羊毛醇0.15g置水浴上融化后倒入苦参总生物碱水溶液中；S4：加入甘油5g搅拌均匀。
Claims (6)
1.一种消炎多用女性阴道泡沫剂，其特征在于：其包括如下重量份数的各组分：
醋酸氯己定 7.5-22.5份；
椰子油脂肪酸二乙醇酰胺 160-180份；
三乙醇胺 100-250份；
复合卵黄抗体 6.5-25份；
两性霉素B 2.4-8.6份；
壳聚糖 7-15份；
鱼腥草提取液 70-200份；
莪术油 50-200份；
苦参碱剂 30-75份；
去离子水 500-6000份。
2.根据权利要求1所述的一种消炎多用女性阴道泡沫剂，其特征在于：所述复合卵黄抗体为卵黄抗体粉，其制备方法如下：S1：将所述鸡蛋经清洗、打蛋分离后得到卵黄；S2：均质、巴氏杀菌；S3：进行喷雾干燥，获得卵黄抗体粉。
3.根据权利要求1所述的一种消炎多用女性阴道泡沫剂，其特征在于：其还包括如下重量份数的各组分：甲硝唑6.5-8份；克霉唑4.5-6.5份。
4.根据权利要求1所述的一种消炎多用女性阴道泡沫剂，其特征在于：所述三乙醇胺精制方法为将三乙醇胺含量在80%以上的工业品用水蒸气蒸馏除去乙醇胺，加入氢氧化钠使三乙醇胺成碱金属盐而析出，分离后中和，再进行减压蒸馏得纯品。
5.根据权利要求1所述的一种消炎多用女性阴道泡沫剂，其特征在于：所述鱼腥草提取液制备过程包括如下步骤：S1：将新鲜鱼腥草洗净后粉碎、过筛，加入乙醇，在75～100℃回流提取4-6小时，料液重量体积比为1:22～30；S2：将提取液过滤、经真空浓缩至无醇味；S3：在紫外线消毒灯下消毒1-2h。
6.根据权利要求1所述的一种消炎多用女性阴道泡沫剂，其特征在于：所述苦参碱剂制备过程包括如下步骤：S1：取苦参总生物碱6g，加水溶解；S2：以5mol/L盐酸调节PH至6；S3：将十二醇硫酸钠0.12g、十八醇0.2g和羊毛醇0.15g置水浴上融化后倒入苦参总生物碱水溶液中；S4：加入甘油5g搅拌均匀。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010634558.0A CN111617245A (zh) | 2020-07-04 | 2020-07-04 | 一种消炎多用女性阴道泡沫剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010634558.0A CN111617245A (zh) | 2020-07-04 | 2020-07-04 | 一种消炎多用女性阴道泡沫剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111617245A true CN111617245A (zh) | 2020-09-04 |
Family
ID=72267774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010634558.0A Pending CN111617245A (zh) | 2020-07-04 | 2020-07-04 | 一种消炎多用女性阴道泡沫剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111617245A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2050045A1 (en) * | 1991-08-23 | 1993-02-24 | Jean Heusser | Pharmaceutical, vaginal applicable preparation and a process for its preparation |
| CN1709243A (zh) * | 2005-07-02 | 2005-12-21 | 杨喜鸿 | 含有依布硒啉的阴道内使用药物及其用途 |
| CN1827105A (zh) * | 2005-10-18 | 2006-09-06 | 郑起平 | 妇得康泡沫剂及其制备方法 |
| CN101579432A (zh) * | 2008-05-15 | 2009-11-18 | 北京法玛赛科医药科技有限公司 | 一种治疗妇科疾病的阴道用凝胶剂及其制备方法 |
| CN108653729A (zh) * | 2018-08-27 | 2018-10-16 | 广州汇高生物科技有限公司 | 一种阴道泡沫剂及其应用 |
-
2020
- 2020-07-04 CN CN202010634558.0A patent/CN111617245A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2050045A1 (en) * | 1991-08-23 | 1993-02-24 | Jean Heusser | Pharmaceutical, vaginal applicable preparation and a process for its preparation |
| CN1709243A (zh) * | 2005-07-02 | 2005-12-21 | 杨喜鸿 | 含有依布硒啉的阴道内使用药物及其用途 |
| CN1827105A (zh) * | 2005-10-18 | 2006-09-06 | 郑起平 | 妇得康泡沫剂及其制备方法 |
| CN101579432A (zh) * | 2008-05-15 | 2009-11-18 | 北京法玛赛科医药科技有限公司 | 一种治疗妇科疾病的阴道用凝胶剂及其制备方法 |
| CN108653729A (zh) * | 2018-08-27 | 2018-10-16 | 广州汇高生物科技有限公司 | 一种阴道泡沫剂及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109078165B (zh) | 一种用于女性私处护理的组合物及其制备方法与应用 | |
| US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
| CN111202822A (zh) | 一种妇科外用抗菌喷剂及其制备方法 | |
| CN110478477A (zh) | 一种促进女性生殖健康的中药生物制剂及其制备方法 | |
| WO2017101790A1 (zh) | 用于治疗皮肤瘙痒病症的药物组合物及其应用 | |
| CN102697671B (zh) | 一种抑菌防病的湿巾药水及其制备方法 | |
| KR101951733B1 (ko) | 프로폴리스 및 천연 추출물을 포함하는 여성 청결제용 조성물 및 이의 제조 방법 | |
| CN101417068B (zh) | 一种中药抑菌洗液及其制备方法 | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| CN105168385B (zh) | 一种抗菌止痒的药物组合物及其制备方法 | |
| KR102218823B1 (ko) | 지치 추출물을 포함하는 항알러지용 조성물 | |
| CN109288889A (zh) | 一种抗菌妇科组合物、凝胶及其制备方法 | |
| KR102148808B1 (ko) | 천연 항균제를 포함하는 여성청결제 조성물 | |
| JP5690102B2 (ja) | 泌尿器系疾患予防治療用組成物及びその製造方法 | |
| CN110585418A (zh) | 女性外用消毒精油乳及其生产工艺 | |
| CN102755578B (zh) | 一种治疗妇科疾病的洗液及其制备方法 | |
| CN111617245A (zh) | 一种消炎多用女性阴道泡沫剂 | |
| CN103239676A (zh) | 一种用于防治细菌性阴道病的外用药物组合物 | |
| CN109125424A (zh) | 一种防治奶牛乳房炎的涂膜剂及其制备方法 | |
| KR20190092038A (ko) | 자귀나무 수피 추출물을 유효성분으로 함유하는 항균 활성을 가지는 조성물 및 이를 포함하는 여성청결제 조성물 | |
| CN105943718B (zh) | 一种沉香复方中药组合物及其制备方法、应用 | |
| CN108324920B (zh) | 一种治疗便秘的中药组合物及制备方法 | |
| CN105326954A (zh) | 一种治疗睑缘炎的中药组合物及其制备方法 | |
| CN111588767A (zh) | 一种葡萄柚籽妇科凝胶 | |
| CN111110786A (zh) | 一种褥疮外伤中药及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200904 |
|
| RJ01 | Rejection of invention patent application after publication |